OCGN - NASDAQ

Ocugen, Inc.

OCGN·NASDAQ

$1.30

-5.1%

HealthcareBiotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$440.08M

EPS-0.2300

P/E Ratio-5.65

Earnings Date07/30/2026

ocgn

Sales/Maturities of Investments

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Ocugen, Inc. Competitors Analysis of Sales/Maturities of Investments

OCGN · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Ocugen, Inc. NASDAQ:OCGN	0.00	N/A	N/A	N/A
Compass Therapeutics, Inc. NASDAQ:CMPX	101.28M	-17.8%	N/A	N/A
Alumis Inc. Common Stock NASDAQ:ALMS	447.95M	80.4%	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	2.00M	-68.4%	N/A	10.3%
Neurogene Inc. NASDAQ:NGNE	284.70M	284.7%	N/A	17.0%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	251.17M	12.1%	N/A	N/A
Omeros Corporation NASDAQ:OMER	109.90M	-52.8%	1.9%	6.6%
Fulcrum Therapeutics, Inc. NASDAQ:FULC	211.25M	10.0%	19.1%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	135.04M	-20.3%	9.9%	N/A
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	252.86M	13.3%	46.4%	-5.5%

Ocugen, Inc. Fair Value Envelope

OCGN · NASDAQ

Our analysis suggests that OCGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.3, this represents a potential HIDDEN relative to our calculated worth for Ocugen, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.3

Related Guides

Blog Categories

Continue your OCGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.